Current Advances in The Development of Novel Polymeric Nanoparticles for The Treatment of Neurodegenerative Diseases

Cano, Amanda; Ettcheto, Miren; López-Machado, Ana; Espina, Marta; Souto, Eliana B.; Galindo, Ruth; Camins, Antoni; García, Montse; Turowski, Patric

doi:10.2217/nnm-2019-0443

Cited by 98 publications

(60 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Polymeric nanoparticles (NPs) have attracted considerable interest over recent years due to their properties resulting from their small size [1][2][3]. Advantages of polymeric NPs as drug carriers include their potential use for controlled release, the ability to protect drug and other molecules with biological activity against the environment, improve their bioavailability and therapeutic index [1,4].…”

Section: Introductionmentioning

confidence: 99%

Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology

et al. 2020

View full text Add to dashboard Cite

Polymeric nanoparticles (NPs) are particles within the size range from 1 to 1000 nm and can be loaded with active compounds entrapped within or surface-adsorbed onto the polymeric core. The term “nanoparticle” stands for both nanocapsules and nanospheres, which are distinguished by the morphological structure. Polymeric NPs have shown great potential for targeted delivery of drugs for the treatment of several diseases. In this review, we discuss the most commonly used methods for the production and characterization of polymeric NPs, the association efficiency of the active compound to the polymeric core, and the in vitro release mechanisms. As the safety of nanoparticles is a high priority, we also discuss the toxicology and ecotoxicology of nanoparticles to humans and to the environment.

show abstract

Section: Introductionmentioning

confidence: 99%

Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To overcome all these obstacles, the therapeutic potential of drug-loaded nanocarriers in different neurodegenerative diseases has been explored [150]. The high surface-to-volume ratio of nanocarriers and the possibility of surface functionalization with desired ligands are the two main exploited characteristics of these devices for drug delivery to CNS [150]. In addition, Aβ targeting has been the main objective of nanomedicine to date.…”

Section: Nanocarriers As Therapeutic Tools In Admentioning

confidence: 99%

“…However, these systems also have some disadvantages that limit their use, especially the need for organic solvents during their fabrication. Nevertheless, their pharmacological potential has encouraged many researchers to explore the potential of PNPs for the diagnosis and therapeutic management of different neurodegenerative diseases [150]. Table 4 summarizes recent advances on the preclinical evaluation of state-of-the-art PNPs in AD.…”

Section: Polymeric-based Nanoparticles For Alzheimer's Diseasementioning

confidence: 99%

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

Cano

Turowski²,

Ettcheto

et al. 2021

J Nanobiotechnol

Self Cite

View full text Add to dashboard Cite

Increasing life expectancy has led to an aging population, which has consequently increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of dementia worldwide, is estimated to make up 50–80% of all cases. AD cases are expected to reach 131 million by 2050, and this increasing prevalence will critically burden economies and health systems in the next decades. There is currently no treatment that can stop or reverse disease progression. In addition, the late diagnosis of AD constitutes a major obstacle to effective disease management. Therefore, improved diagnostic tools and new treatments for AD are urgently needed. In this review, we investigate and describe both well-established and recently discovered AD biomarkers that could potentially be used to detect AD at early stages and allow the monitoring of disease progression. Proteins such as NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng / BACE are some of the most promising biomarkers because of their successful use as diagnostic tools. In addition, we explore the most recent molecular strategies for an AD therapeutic approach and nanomedicine-based technologies, used to both target drugs to the brain and serve as devices for tracking disease progression diagnostic biomarkers. State-of-the-art nanoparticles, such as polymeric, lipid, and metal-based, are being widely investigated for their potential to improve the effectiveness of both conventional drugs and novel compounds for treating AD. The most recent studies on these nanodevices are deeply explained and discussed in this review. Graphic Abstract

show abstract

“…One of the main limitations during bacterial neuroinfections treatment is the inability of antibiotics to surpass the BBB and the blood–cerebrospinal fluid barrier (BCSFB), as well as the emerging of antibiotic resistance. To this end, drug targeting approaches are being recently used to overcome these issues [ 117 ]. Getting a local antimicrobial treatment, the concentration of the drug at the site of infection will be improved, as it may modulate drug-pathogen interaction to overcome antibiotic resistance, and enabling 'drug-free' anti-virulence therapy [ 26 ].…”

Section: Recent Polymeric Nanoparticles Against Most Common Human Bacmentioning

confidence: 99%

State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections

et al. 2020

Self Cite

View full text Add to dashboard Cite

Infectious diseases kill over 17 million people a year, among which bacterial infections stand out. From all the bacterial infections, tuberculosis, diarrhoea, meningitis, pneumonia, sexual transmission diseases and nosocomial infections are the most severe bacterial infections, which affect millions of people worldwide. Moreover, the indiscriminate use of antibiotic drugs in the last decades has triggered an increasing multiple resistance towards these drugs, which represent a serious global socioeconomic and public health risk. It is estimated that 33,000 and 35,000 people die yearly in Europe and the United States, respectively, as a direct result of antimicrobial resistance. For all these reasons, there is an emerging need to find novel alternatives to overcome these issues and reduced the morbidity and mortality associated to bacterial infectious diseases. In that sense, nanotechnological approaches, especially smart polymeric nanoparticles, has wrought a revolution in this field, providing an innovative therapeutic alternative able to improve the limitations encountered in available treatments and capable to be effective by theirselves. In this review, we examine the current status of most dangerous human infections, together with an in-depth discussion of the role of nanomedicine to overcome the current disadvantages, and specifically the most recent and innovative studies involving polymeric nanoparticles against most common bacterial infections of the human body.

show abstract

Current Advances in The Development of Novel Polymeric Nanoparticles for The Treatment of Neurodegenerative Diseases

Cited by 98 publications

References 131 publications

Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology

Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges

State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections

Contact Info

Product

Resources

About